Riverside CA Emergency Kit Preparedness Supplies Corporate Solutions Launched

Simpler Life, an emergency survival supplies company based in Redlands, California, launched an updated range of preparedness solutions for clients in Riverside, Redlands, San Bernardino and other areas. The company offers complete emergency kits for residents, corporate and institutional clients.

Redlands, United States - September 13, 2017 /PressCable/ —

Simpler Life, a Redlands, California company specializing in survival and preparedness solutions, announced an updated range of services following the latest severe weather conditions. The company offers a wide range of survival supplies, emergency kits and various other items, many of which will be presented at two disaster planning conventions in Sacramento and Anaheim.

More information can be found at https://simplerlife.com.

Emergency preparedness is essential to avoid potentially life-threatening situations during hurricanes, flooding, earthquakes and other extreme events. Simpler Life is a leading survival supplies and training company with more than 35 years of experience providing preparedness solutions for various prestigious clients, including NASA, Alaska Air, Boeing, Oroweat, Nestle, Ford, Capital Group and various others.

In light of the recent extreme weather events, the company has announced an updated range of survival products as part of its continuous campaign to provide quality preparedness solutions for residents and companies in Riverside, San Bernardino, Redlands, Sacramento, Anaheim and other areas.

The company offers public access bleeding control kits available in various sizes, portable first aid kits, water filtration tools, emergency food supplies and many other products. Specialized kits for vehicles, offices and hospitals are also available.

Simpler Life will present its products at two disaster planning conventions held between September 18 – 21. The company will be among the exhibitors at the Disaster Planning for California Hospitals on September 18- 20 at the Sacramento Convention Center, and at the American Red Cross Disaster Preparedness Academy at the Anaheim Convention Center on September 21. Additional details can be found at https://www.calhospital.org/disaster-planning.

Owner Bod Snedaker emphasized the company’s dedication to providing quality emergency supplies for all types of clients:

“It is evident that disaster can strike at any time – while we are at work, driving down the road, at home, at school or watching our kids playing soccer or baseball. Just being prudent , let alone the moral and physical implications of not being prepared, should drive us all to work at looking ahead and being prepared – whether it is for our family, for our employees, for our city, or for our state. That is why Simpler Life exists – we want to help you in your quest to be able to provide and protect in times of emergency.”

Interested parties can find more information by visiting the above-mentioned websites.

Contact Info:
Name: Bob Snedaker
Email: info@simplerlife.com
Organization: Simpler Life
Address: 2035 W Park Ave, Redlands, California 92373, United States
Phone: +1-800-266-7737

For more information, please visit https://simplerlife.com

Source: PressCable

Release ID: 239005

Latest News

EU charges Merck KGaA, GE, Canon of misleading merger info

Nov 22, 2017

By Foo Yun CheeBRUSSELS (Reuters) - General Electric , German drugmaker Merck KGaA , and Japan's Canon risk hefty fines after EU antitrust regulators accused them of providing misleading information during separate merger deals.The European Commission said on Thursday that it had sent three separate charge sheets known as statements of objections to General Electric, Merck KGaA and Canon after investigations showed breaches of the bloc's merger rules.While the charges will not affect the EU approvals of the deals, they could lead to fines up to 1 percent of global revenue for Merck KGaA and General Electric, and up to...

Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion

Nov 22, 2017

By Sam NusseyTOKYO (Reuters) - Konica Minolta Inc said it was purchasing U.S. diagnostics company Ambry Genetics in a deal valued at up to $1 billion - an acquisition that marks a strategic shift for the Japanese firm's healthcare business as it seeks a leading position in precision medicine.The deal is the largest ever for the photocopier maker, which has been seeking to diversify away its office equipment business. It pulled out of cameras about a decade ago.Konica Minolta said its advanced imaging technology complemented privately held Ambry's genetic testing capabilities, with initial applications for combining the technologies seen in...

Oxford BioMedica wins big contract for Novartis cell therapy

Nov 22, 2017

LONDON (Reuters) - Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability.The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukemia that is expected to reach the market this year.A U.S. advisory panel will discuss the case for approving CTL019 at a meeting...

Novartis receives EU approval for Cosentyx label update

Nov 22, 2017

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday. (Reporting by Silke Koltrowitz)

FDA puts hold on Merck multiple myeloma trials after deaths

Nov 22, 2017

(Reuters) - Merck & Co said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.The rare setback for Keytruda sent Merck shares more than 1 percent lower.Merck has been on a roll with the medicine, jumping to the front of the pack of companies with new immuno-oncology drugs, particularly after Keytruda extended survival as an initial treatment for advanced lung cancer, by far the largest oncology market. Bristol-Myers...

Top News
You May Need To Know

About Us

The Healthier Web delivers accurate and up-to-date health information through medical content and insights from experts. Feel the ‘ohm’ here in The Healthier Web.

Contact us: sales@thehealthierweb.com